Publicaciones en las que colabora con Gloria González Aseguinolaza (29)

2024

  1. Deciphering the Role of Post-Translational Modifications and Cellular Location of Hepatitis Delta Virus (HDV) Antigens in HDV-Mediated Liver Damage in Mice

    Viruses, Vol. 16, Núm. 3

  2. Efficient and safe therapeutic use of paired Cas9-nickases for primary hyperoxaluria type 1

    EMBO molecular medicine, Vol. 16, Núm. 1, pp. 112-131

  3. Protective role of RIPK1 scaffolding against HDV-induced hepatocyte cell death and the significance of cytokines in mice

    PLoS Pathogens, Vol. 20, Núm. 5

2023

  1. Cardiac Progenitor Cell Exosomal miR-935 Protects against Oxidative Stress

    Cells, Vol. 12, Núm. 18

  2. Microglia and astrocyte activation is region-dependent in the α-synuclein mouse model of Parkinson's disease

    GLIA, Vol. 71, Núm. 3, pp. 571-587

  3. Stabilization of 14-3-3 protein-protein interactions with Fusicoccin-A decreases alpha-synuclein dependent cell-autonomous death in neuronal and mouse models

    Neurobiology of Disease, Vol. 183

  4. Topoisomerase Inhibitors Increase Episomal DNA Expression by Inducing the Integration of Episomal DNA in Hepatic Cells

    Pharmaceutics, Vol. 15, Núm. 10

2021

  1. Aav-hdv: An attractive platform for the in vivo study of hdv biology and the mechanism of disease pathogenesis

    Viruses, Vol. 13, Núm. 5

2020

  1. Effect of heart ischemia and administration route on biodistribution and transduction efficiency of AAV9 vectors

    Journal of Tissue Engineering and Regenerative Medicine, Vol. 14, Núm. 1, pp. 123-134

  2. TNF-alpha inhibition ameliorates HDV-induced liver damage in a mouse model of acute severe infection

    JHEP Reports, Vol. 2, Núm. 3

2019

  1. Danio rerio as model organism for adenoviral vector evaluation

    Genes, Vol. 10, Núm. 12

2018

  1. CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I

    Nature Communications, Vol. 9, Núm. 1

  2. Erratum to “A new HDV mouse model identifies mitochondrial antiviral signaling protein (MAVS) as a key player in IFN-β induction” [J Hepatol 67 (2017) 669–679] (S0168827817320469) (10.1016/j.jhep.2017.05.010))

    Journal of Hepatology

2017

  1. A new HDV mouse model identifies mitochondrial antiviral signaling protein (MAVS) as a key player in IFN-β induction

    Journal of Hepatology, Vol. 67, Núm. 4, pp. 669-679

  2. Adeno-associated viral vectors serotype 8 for cell-specific delivery of therapeutic genes in the central nervous system

    Frontiers in Neuroanatomy, Vol. 11

2016

  1. Complementary effects of interleukin-15 and alpha interferon induce immunity in hepatitis B virus transgenic mice

    Journal of Virology, Vol. 90, Núm. 19, pp. 8563-8574

  2. Identification of IFN-γ-producing T cells as the main mediators of the side effects associated to mouse interleukin-15 sustained exposure

    Oncotarget, Vol. 7, Núm. 31, pp. 49008-49026

2015

  1. A RIG-I 2CARD-MAVS200 Chimeric Protein Reconstitutes IFN-β Induction and Antiviral Response in Models Deficient in Type i IFN Response

    Journal of Innate Immunity, Vol. 7, pp. 466-481

  2. Chronic exposure to IFNα drives medullar lymphopoiesis towards t-cell differentiation in mice

    Haematologica, Vol. 100, Núm. 8, pp. 1014-1022

2013

  1. IL12-Mediated Liver Inflammation Reduces the Formation of AAV Transcriptionally Active Forms but Has No Effect over Preexisting AAV Transgene Expression

    PLoS ONE, Vol. 8, Núm. 7